ClinicalTrials.gg
CompletedNCT05059002Updated Feb 4, 2025

EpiWatch: Evaluation of a Non-EEG Physiological Signal Based Seizure Monitoring System

An interventional study of Physiological signal monitoring and seizure detection in Epilepsy, Tonic-Clonic, sponsored by EpiWatch, Inc.. Completed at 1 site in United States. Open to participants aged 5 Years and older. Per ClinicalTrials.gov, last updated 2025-02-04.

Sponsored by EpiWatch, Inc. · Not applicable, Interventional, and Supportive care

From the registry’s dates

  • Primary completion was Oct 2023, 3 years ago, and no results have been posted to the registry.
Phase
Not applicable
Study type
Interventional
Enrollment
242
Allocation
Not applicable
Ages
5 Years and older
Sex
All
01

Study summary

To demonstrate the safety and effectiveness of the EpiWatch device in identifying tonic-clonic (TC) seizures, notifying a third-party of TC seizure occurrence, and collecting non-EEG physiological data for subsequent review during patient hospitalization in an epilepsy monitoring unit (EMU).

Read the detailed description

To demonstrate the safety and effectiveness of the EpiWatch device in identifying tonic-clonic (TC) seizures, notifying a third-party of TC seizure occurrence, and collecting non-EEG physiological data for subsequent review, during patient hospitalization in an epilepsy monitoring unit (EMU).

Eligible subjects will be issued an EpiWatch device upon admittance into the EMU. The events detected by the EpiWatch will be compared to TC seizures as determined by epileptologists' interpretation of video-EEG recorded for the subject to determine the effectiveness of EpiWatch in detecting TC seizures. EMU standard care practices will not be modified for subjects.

02

Conditions studied

  • Epilepsy, Tonic-Clonic

Keywords

  • Seizure Detection
  • Seizure
  • Digital Health
03

In context

Epilepsy, Tonic-Clonic

23 studies on the registry are indexed under Epilepsy, Tonic-Clonic; 3 are open to participants now.

This study's enrollment of 242 is above the median of 94 across 20 interventional studies indexed under Epilepsy, Tonic-Clonic.

Browse Epilepsy, Tonic-Clonic studies →

Lead sponsor

This is the only study on the registry with EpiWatch, Inc. as lead sponsor.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
5 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Admitted to a site EMU for video-EEG monitoring
  • Age five and older at the time of enrollment
  • Has a clinical history of tonic-clonic (TC) seizures or potential for TC seizures
  • Willing and able to comply with study procedures

Exclusion criteria

Exclusion Criteria:

  • Has participated previously in EpiWatch development studies or contributed any data to the prior development or evaluation of the detector being tested or previous detectors
  • Has any condition that would prevent proper wearing of the watch, its free movement during a seizure, or create discomfort from wearing the watch
  • Inability or unwillingness to comply with study procedures
05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
242 participants (actual)

Study arms

  • Other
    Monitored Subjects

    Single arm study of subjects that have been issued an EpIWatch

    Device: Physiological signal monitoring and seizure detection

Interventions

  • DevicePhysiological signal monitoring and seizure detection

    Data collection and as an adjunct to other methods of seizure monitoring

06

What researchers measure

Primary outcomes

  1. Comparison of video-EEG to EpiWatch Results for PPA

    Lower bound of 95% confidence interval of the positive percent agreement (PPA) \> 80%, as determined by comparison to subject video-EEG events as adjudicated based on majority rule of three independent expert reviewers.

    Time frame: 6 months

  2. Comparison of video-EEG to EpiWatch results for FAR

    Upper bound of 95% confidence interval of the false alarm rate (FAR) \<.71, as determined by comparison to subject video-EEG events as adjudicated based on majority rule of three independent expert reviewers.

    Time frame: 6 months

Secondary outcomes

  1. Pediatric Ambulation Positive Percent Agreement

    Estimate the PPA in pediatric participants in ambulation in addition to at rest

    Time frame: 6 months

  2. Pediatric Ambulation False Alarm Rate

    Estimate the False Alarm Rate in pediatric participants in ambulation in addition to rest

    Time frame: 6 months

07

Study locations

1 site
  • Johns Hopkins Medicine
    Baltimore, Maryland 21205, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Feb 4, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05059002
Lead sponsor
EpiWatch, Inc.
Responsible party
Sponsor
First posted
Sep 28, 2021
Start date
Sep 20, 2021
Primary completion
Oct 31, 2023
Completion
Oct 31, 2023
Last update
Feb 4, 2025

Study contacts

Gregory L Krauss, MD
principal investigator · Johns Hopkins University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion